Advertisment
Arrowhead Pharmaceuticals announces participation in major global healthcare and scientific conferences in November 2024
Arrowhead Pharmaceuticals, Inc. announced that it is scheduled to participate in the following upcoming events:
15th Annual American Conference on Pharmacometrics (ACoP 2024) – November 10-13, 2024
Title: Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Patients with Severe Hypertriglyceridemia
Presenter: Jack Shi
Session: Poster
Title: Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Atherosclerotic Cardiovascular Disease (ASCVD) in Patients with Mixed Hyperlipidemia
Presenter: Jack Shi
Session: Poster
UBS Global Healthcare Conference – November 11-14, 2024
Type: Fireside Chat Presentation
Date/Time: November 12, 2024, 3:30 p.m. PST
TIDES Europe – Oligonucleotide and Peptide Therapeutics – November 12-14, 2024
Title: Novel TRiM™ Platform for Oligonucleotide Delivery to Trabecular Meshwork via Local Intracameral Administration
Date/Time: November 14, 2024, 14:00 CET
Presenter: Jing Chen
Session: Oligonucleotide Discovery, Preclinical and Clinical
American Heart Association (AHA) Scientific Sessions 2024 – November 16-18, 2024
Title: PALISADE: A Phase 3 Study to Assess the Efficacy and Safety of Plozasiran in adults with Genetically or Clinically-Defined Familial Chylomicronemia Syndrome (FCS) at high risk of Acute Pancreatitis (AP)
Date/Time: November 16, 2024, 2:04 pm CST
Presenter: Gerald Watts
Session: Featured Science: Novel Approaches to Managing Lipid Risk
Title: Plozasiran and Triglyceride Levels in Hypertriglyceridemia: Long-Term Efficacy and Safety Data from Subjects in an Open-Label Extension Trial (MUIR and SHASTA-2 OLE)
Date/Time: November 18, 2024, 10:45 am CST
Presenter: Christie Ballantyne
Session: New Insights in Lipids and lipid lowering therapies
The Liver Meeting 2024 – American Association for the Study of Liver Diseases (AASLD) – November 15-19, 2024
Title: Long-Term Safety and Efficacy of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease Enrolled in the Phase 2 Placebo-Controlled SEQUOIA Trial
Date/Time: November 18, 2024, 8:00 am PST
Presenter: Virginia Clark
Session: Metabolic and Genetic Disease
Title: Digital Image Quantification of Collagen Proportionate Area Correlates with METAVIR Fibrosis Stage and Liver Stiffness Measurement Via FibroScan® in Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Date/Time: November 18, 2024, 8:00 am PST
Presenter: Cynthia Behling
Session: Metabolic and Genetic Disease
Title: Concordance of Histological and Liquid Chromatography Mass Spectrometry-Based Intrahepatic Z-Alpha-1 Antitrypsin (Z-AAT) Burden Assessments in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Date/Time: November 18, 2024, 8:00 am PST
Presenter: Rohit Loomba
Session: Metabolic and Genetic Disease
Jefferies London Healthcare Conference – November 19-21, 2024
Type: Fireside Chat Presentation
Date/Time: November 20, 2024, 8:00 am GMT
